Abbott Laboratories (ABT) Position Boosted by Dai Ichi Life Insurance Company Ltd

Dai Ichi Life Insurance Company Ltd grew its holdings in shares of Abbott Laboratories (NYSE:ABT) by 2.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 168,276 shares of the healthcare product maker’s stock after purchasing an additional 4,602 shares during the period. Dai Ichi Life Insurance Company Ltd’s holdings in Abbott Laboratories were worth $8,180,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of the company. State Street Corp boosted its position in shares of Abbott Laboratories by 18.9% during the 1st quarter. State Street Corp now owns 80,499,469 shares of the healthcare product maker’s stock valued at $3,574,987,000 after purchasing an additional 12,806,535 shares in the last quarter. Alliancebernstein L.P. boosted its position in shares of Abbott Laboratories by 7.7% during the 2nd quarter. Alliancebernstein L.P. now owns 11,607,121 shares of the healthcare product maker’s stock valued at $564,222,000 after purchasing an additional 830,610 shares in the last quarter. Boston Partners boosted its position in shares of Abbott Laboratories by 28.1% during the 2nd quarter. Boston Partners now owns 10,516,502 shares of the healthcare product maker’s stock valued at $511,207,000 after purchasing an additional 2,304,467 shares in the last quarter. Independent Franchise Partners LLP boosted its position in shares of Abbott Laboratories by 0.8% during the 2nd quarter. Independent Franchise Partners LLP now owns 9,828,141 shares of the healthcare product maker’s stock valued at $477,745,000 after purchasing an additional 76,935 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its position in shares of Abbott Laboratories by 33.8% during the 1st quarter. Ameriprise Financial Inc. now owns 8,823,399 shares of the healthcare product maker’s stock valued at $391,841,000 after purchasing an additional 2,231,316 shares in the last quarter. Institutional investors own 71.10% of the company’s stock.

Shares of Abbott Laboratories (NYSE:ABT) opened at $55.98 on Friday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.26 and a current ratio of 2.69. Abbott Laboratories has a 52 week low of $37.42 and a 52 week high of $56.69. The company has a market cap of $97,438.84, a PE ratio of 23.23, a price-to-earnings-growth ratio of 2.10 and a beta of 1.06.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Wednesday, October 18th. The healthcare product maker reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.01. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. The company had revenue of $6.83 billion during the quarter, compared to analyst estimates of $6.72 billion. During the same period in the prior year, the firm earned $0.59 earnings per share. The business’s quarterly revenue was up 28.8% on a year-over-year basis. equities research analysts predict that Abbott Laboratories will post 2.49 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th were given a $0.265 dividend. This represents a $1.06 dividend on an annualized basis and a dividend yield of 1.89%. The ex-dividend date was Thursday, October 12th. Abbott Laboratories’s dividend payout ratio (DPR) is 83.47%.

ABT has been the subject of several research reports. Bank of America restated a “buy” rating and set a $60.00 price objective (up previously from $56.00) on shares of Abbott Laboratories in a research report on Wednesday, October 4th. Royal Bank Of Canada restated a “buy” rating and set a $55.00 price objective on shares of Abbott Laboratories in a research report on Tuesday, October 3rd. Cowen restated a “buy” rating on shares of Abbott Laboratories in a research report on Sunday, September 24th. Zacks Investment Research upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a research report on Friday, September 22nd. Finally, Jefferies Group restated a “buy” rating and set a $65.00 price objective on shares of Abbott Laboratories in a research report on Thursday, October 19th. Eight research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $56.81.

In other news, insider Sharon J. Bracken sold 2,188 shares of the stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $56.12, for a total value of $122,790.56. Following the completion of the sale, the insider now directly owns 25,618 shares of the company’s stock, valued at $1,437,682.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jaime Contreras sold 52,700 shares of the stock in a transaction that occurred on Friday, September 22nd. The stock was sold at an average price of $51.97, for a total transaction of $2,738,819.00. Following the completion of the sale, the insider now directly owns 58,739 shares of the company’s stock, valued at $3,052,665.83. The disclosure for this sale can be found here. Insiders sold 311,127 shares of company stock valued at $16,958,579 over the last three months. 0.76% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/12/03/abbott-laboratories-abt-position-boosted-by-dai-ichi-life-insurance-company-ltd.html.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

What are top analysts saying about Abbott Laboratories? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Abbott Laboratories and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit